Description: KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.
Home Page: www.kalvista.com
55 Cambridge Parkway
Cambridge,
MA
02142
United States
Phone:
857 999 0075
Officers
| Name | Title |
|---|---|
| Mr. Benjamin L. Palleiko | CEO & Director |
| Dr. Christopher M. Yea Ph.D. | Chief Development Officer |
| Dr. Paul K. Audhya M.B.A., M.D. | Chief Medical Officer |
| Mr. Brian Piekos | Chief Financial Officer |
| Mr. Ryan Baker | Head of Investor Relations |
| Mr. Brian Krex J.D. | General Counsel |
| Jarrod Aldom | Vice President of Corporate Communications |
| Ms. Rachel M. Morten | Senior Vice President of Regulatory Affairs & QA |
| Dr. Michael D. Smith Pharm.D. | Senior Vice President of Development |
| Ms. Nicole Sweeny | Chief Commercial Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.402 |
| Price-to-Sales TTM: | 103.7767 |
| IPO Date: | |
| Fiscal Year End: | April |
| Full Time Employees: | 150 |